CD274 and hepatocellular carcinoma: In contrast, the CheckMate 040 trial demonstrated that the ORR were independent of PD-L1 expression on tumor cells, although higher levels of tumor PD-L1 expression were associated with improved OS in HCC patients receiving nivolumab [10].